Global Drug Based on Gene Therapy Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Drug Based on Gene Therapy Market Research Report 2024
Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.
According to Mr Accuracy reports new survey, global Drug Based on Gene Therapy market is projected to reach US$ 49770 million in 2029, increasing from US$ 9063.6 million in 2022, with the CAGR of 27.5% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Drug Based on Gene Therapy market research.
The Drug Based on Gene Therapy market is primarily driven by the revolutionary potential of gene therapy to address genetic disorders at their root cause, offering a new paradigm for treating previously incurable conditions. Gene therapy involves introducing genetic material into a patient's cells to correct or replace faulty genes, aiming to restore normal cellular function. The increasing understanding of the genetic basis of diseases, coupled with advancements in gene delivery methods and genome editing techniques, contributes to market growth. Moreover, the demonstrated benefits of gene therapy in providing targeted and long-lasting treatments, overcoming limitations of traditional pharmacological approaches, and offering hope to patients with rare genetic disorders further propel adoption. However, challenges include optimizing gene delivery efficiency, addressing potential immune responses, and ensuring the long-term safety and durability of gene-based treatments. Navigating regulatory pathways, conducting rigorous clinical trials, and addressing ethical considerations are ongoing concerns. The market's success relies on continuous research in genetic medicine, collaborations between biotechnology companies and research institutions, and comprehensive education on the benefits and potential challenges of using gene therapy-based drugs while addressing the evolving challenges associated with precision medicine and personalized treatments.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Drug Based on Gene Therapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
bluebird bio
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
Segment by Type
Viral Gene Therapy
Non-viral Gene Therapy
Neurological Diseases
Cancer
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Drug Based on Gene Therapy report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Drug Based on Gene Therapy market is projected to reach US$ 49770 million in 2029, increasing from US$ 9063.6 million in 2022, with the CAGR of 27.5% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Drug Based on Gene Therapy market research.
The Drug Based on Gene Therapy market is primarily driven by the revolutionary potential of gene therapy to address genetic disorders at their root cause, offering a new paradigm for treating previously incurable conditions. Gene therapy involves introducing genetic material into a patient's cells to correct or replace faulty genes, aiming to restore normal cellular function. The increasing understanding of the genetic basis of diseases, coupled with advancements in gene delivery methods and genome editing techniques, contributes to market growth. Moreover, the demonstrated benefits of gene therapy in providing targeted and long-lasting treatments, overcoming limitations of traditional pharmacological approaches, and offering hope to patients with rare genetic disorders further propel adoption. However, challenges include optimizing gene delivery efficiency, addressing potential immune responses, and ensuring the long-term safety and durability of gene-based treatments. Navigating regulatory pathways, conducting rigorous clinical trials, and addressing ethical considerations are ongoing concerns. The market's success relies on continuous research in genetic medicine, collaborations between biotechnology companies and research institutions, and comprehensive education on the benefits and potential challenges of using gene therapy-based drugs while addressing the evolving challenges associated with precision medicine and personalized treatments.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Drug Based on Gene Therapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
bluebird bio
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
Segment by Type
Viral Gene Therapy
Non-viral Gene Therapy
Segment by Application
Neurological Diseases
Cancer
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Drug Based on Gene Therapy report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source